You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 126 No. 10, October 2008 TABLE OF CONTENTS
  Archives
  •  Online Features
  Small Case Series
 This Article
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (1)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Ophthalmological Disorders, Other
 •Ophthalmological Procedures, Other
 •Radiation Therapy
 •Drug Therapy
 •Adverse Effects
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Conjunctival Autograft Failure in Eyes Previously Exposed to ß-Radiation or Mitomycin

Nagi N. Assaad, MBBS, BSc(Med), MBiomedE; Minas T. Coroneo, MD, MS, MSc, FRACS, FRANZCO

Arch Ophthalmol. 2008;126(10):1460-1461.

For reasons of efficacy and long-term safety, conjunctival or limbal conjunctival autograft surgery is generally regarded as the procedure of choice for the treatment of primary and recurrent pterygia.1-2 Although surgical management of pterygium has traditionally relied on destructive procedures (excision and treatment with ß-radiation or chemotherapy), reconstructive approaches have come into use more recently. It is generally accepted that recurrence rates are higher for surgery of recurrent as compared with primary pterygium, but it remains uncertain as to why this should be the case. A contributing factor may relate to adjunctive measures used during the initial surgery, particularly if a conjunctival autograft is used in a subsequent procedure.

We describe 3 patients for whom graft failure occurred following previous ß-radiation or mitomycin used as adjunctive therapy in the initial surgical management for pterygium. This complication does not appear to have been previously reported.

Report of Cases

Case 1

A frequent surfer and lifeguard had a history of having undergone surgery for a left nasal pterygium in 1989 and in 1994. The pterygium had recurred again and he had developed diplopia in left lateral gaze. A left nasal pterygium extended onto his cornea approximately 2 mm, and a 1-mm left temporal pterygium was noted. During his first surgical procedure, ß-radiation therapy had been used with a dose of 20 Gy (to convert to rads, multiply by 100) applied to the excision site. After his second procedure, during which excision with a free conjunctival graft was performed, the graft was noted to be unhealthy at 1 week; the conjuctival graft subsequently sloughed. The pterygium was reexcised, and a lamellar corneal button was used to repair the defect.

Case 2

This patient was seen in 2007 with a recurrent right nasal pterygium. She had undergone surgery for this pterygium on 3 previous occasions, once in 1992 and twice in 1994. Bare sclera excision was performed each time. Adjunctive ß-radiation treatment with a dose of 14 Gy was used with the initial procedure. A family history of pterygium was also noted. She underwent a second excision with limbal conjunctival autograft and a postoperative course of hyperbaric oxygen therapy. Nine days after surgery, the graft detached from the limbus and appeared to be ischemic. The graft was resutured; however, it became inflamed and again detached (Figure). Recurrence of the pterygium was noted 8 weeks postoperatively.


Figure 1
View larger version (99K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Figure. Patient 2, 5 days after resuturing of the detached limbal conjunctival autograft. There is marked inflammation in the surrounding tissue and the ischemic graft has again detached from the limbus.


Case 3

This patient was observed 18 months after initial excision of a right nasal pterygium. Mitomycin, 0.04%, for 5 minutes, had been applied to the excision site intraoperatively at the initial excision. Two weeks before our seeing this patient, a free conjunctival graft had been placed over an area of scleral thinning at the site of previous surgery. The conjunctival graft had become necrotic and eventually sloughed. The area was repaired with a 5-mm lamellar corneal graft 3 months after our first having observed this patient. Eighteen months later, an area superior to the lamellar graft had also melted and was repaired with a second 5-mm lamellar graft and a sliding conjunctival flap.


Comment

To the best of our knowledge, conjunctival autograft failure in the management of a recurrent pterygium where the graft site has previously undergone irradiation or mitomycin treatment has not previously been reported. Because irradiation can result in an obliterative endarteritis in exposed tissues, it is commonly recognized as a fac tor in graft failure elsewhere. In fact, as noted by Cameron,3 the aim of using irradiation in the management of pterygium was to destroy episcleral vessels that could potentially provide nutrition for a recurrent pterygium.

It should be noted that the doses of ß-radiation used in the treatment of patients described herein were not excessive. It has been shown that following limbal conjunctival autografting, the graft may be perfused from the underlying episcleral vascular bed as early as 1 week postoperatively.4 It is almost certain that this vascular bed is deficient after irradiation and, therefore, graft failure in this setting should come as no surprise. Interestingly, Cameron3 described a case of partial sloughing of a mucous membrane graft over an area of avascular sclera resulting from previous ß-radiation treatment applied at the time of pterygium surgery.

Furthermore, there may be similarities between irradiation and antimetabolites such as mitomycin in their action on conjunctival and episcleral vasculature. Mitomycin is cytotoxic to vascular endothelial cells in vitro,5 and clinically there may be loss of vascularity after application of mitomycin in glaucoma filtering surgery.

None of the patients described here showed any clinical signs of underlying scleral inflammation or necrosis. Therefore, this appears to be a separate entity from surgically induced necrotizing scleritis, a condition that may also cause conjunctival autograft failure after pterygium surgery.6

In deciding on the optimal surgical management for pterygium, use of adjunctive destructive techniques should be carefully considered. In addition to the risk of sight-threatening complications such as scleral necrosis and infective scleritis, it appears that these techniques also interfere with future surgical management in cases of recurrence, as described here. Reconstructive surgery using a limbal conjunctival autograft can provide excellent results for both primary and recurrent pterygia; however, the procedure is time consuming and there is considerable variation in technique among surgeons.

In the setting of previous irradiation or mitomycin therapy, there may be a role for preoperative assessment of anterior segment circulation with indocyanine green angiography7 before considering autograft surgery. Because use of amniotic membrane grafts appears to delay vascularization as compared with a conjunctival autograft, this method should also be reconsidered in the surgery of recurrent pterygia. These considerations reduce surgical options for treating recurrent pterygium, and we believe that methods to improve graft survival after pterygium surgery in this setting should be considered.


AUTHOR INFORMATION

Correspondence: Dr Coroneo, Department of Ophthalmology, The University of New South Wales and Prince of Wales Hospital, Randwick, New South Wales, Australia 2031 (m.coroneo{at}unsw.edu.au).

Author Contributions: Drs Assaad and Coroneo had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Financial Disclosure: None reported.


REFERENCES

1. Coroneo MT, Di Girolamo N, Wakefield D. The pathogenesis of pterygia. Curr Opin Ophthalmol. 1999;10(4):282-288. FULL TEXT | PUBMED
2. Ang LP, Chua JL, Tan DT. Current concepts and techniques in pterygium treatment. Curr Opin Ophthalmol. 2007;18(4):308-313. FULL TEXT | WEB OF SCIENCE | PUBMED
3. Cameron ME. Pterygium throughout the World. Springfield, IL: Charles C. Thomas; 1965:49, 89,160-162.
4. Chan CM, Chew PT, Alsagoff Z, Wong JS, Tan DT. Vascular patterns in pterygium and conjunctival autografting: a pilot study using indocyanine green anterior segment angiography. Br J Ophthalmol. 2001;85(3):350-353. FREE FULL TEXT
5. Smith S, D'Amore PA, Dreyer EB. Comparative toxicity of mitomycin C and 5-fluorouracil in vitro. Am J Ophthalmol. 1994;118(3):332-337. WEB OF SCIENCE | PUBMED
6. Sridhar MS, Bansal AK, Rao GN. Surgically induced necrotizing scleritis after pterygium excision and conjunctival autograft. Cornea. 2002;21(3):305-307. FULL TEXT | WEB OF SCIENCE | PUBMED
7. Küçükerdönmez C, Akova YA, Altinors DD. Vascularization is more delayed in amniotic membrane graft than conjunctival autograft after pterygium excision. Am J Ophthalmol. 2007;143(2):245-249. FULL TEXT | WEB OF SCIENCE | PUBMED

SECTION EDITOR: W. RICHARD GREEN, MD



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.